Relevant bibliographies by topics / Long-Term efficaccy / Journal articles
To see the other types of publications on this topic, follow the link: Long-Term efficaccy.

Journal articles on the topic 'Long-Term efficaccy'

Author: Grafiati
Published: 14 December 2024

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Long-Term efficaccy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Križić, Marija, Tajana Silovski, Marina Popović, and Natalija Dedić Plavetić. "Abstract P4-01-39: Real-world efficaccy of dual antiHER2 therapy in first line metastatic HER2-positive breast cancer and the possibility of prediction of long-term response." Cancer Research 83, no. 5_Supplement (March 1, 2023): P4–01–39—P4–01–39. http://dx.doi.org/10.1158/1538-7445.sabcs22-p4-01-39.

Full text
Abstract:
Abstract Background: Although huge progress has been made in treating HER2-positive metastatic breast cancer in the last decade, it remains an incurable disease. Dual anti-HER2 therapy with pertuzumab and trastuzumab combined with chemotherapy represents the standard first line treatment of metastatic HER2-positive breast cancer, in view of the impressive CLEOPATRA study results. The aim of this study was to analyze the efficacy of dual antiHER2 therapy in real-world clinical practice and determine the differences in the clinicopathological characteristics of the long-term responders in comparison with short-term responders. Methods: Retrospective analysis of dual antiHER2 therapy efficacy was done and correlated to clinical and pathological characteristics of patients with different duration of response (DoR) in the first line metastatic HER2-positive breast cancer. The study was conducted at the UHC Zagreb, Croatia and approved by the Ethics Committee. Long-term responders were defined as patients with a duration of response (DoR) to dual antiHER2 therapy ≥ 36 months, and short-term responders were defined as patients with DoR ≤ 12 months. Progression-free survival was estimated using the Kaplan-Meier method. The reverse Kaplan-Meier method was used to estimate median follow-up duration. The non-parametric Chi-Square test (between categorical variables) and Mann-Whitney U-test (between continuous variables) were used to determine the differences between long-term and short-term responders groups. The significance level was set at p < 0.05. Results: Altogether, 128 patients treated with dual antiHER2 therapy for HER2-positive metastatic breast cancer from October 2015 to May 2022 were included in the study. By data cut-off, 50.8 % (N=63) of patients had progressed or died. The median follow-up time was 36 months. The median PFS was 31 months for the total cohort (95% CI 22.6 -39.3). Overall, 29 patients among the long-term responders and 32 patients in the short-term responders group were identified. A comparison of clinical and pathological characteristics between the two groups is shown in Table 1. Even though patients in the group of long-term responders were younger (54.5 years vs. 56.5 years), had less visceral involvement (69 % vs. 81.3%), and were more often trastuzumab ”naive“ (75.9% vs. 68.7%), no statistically significant differences were found between the two groups. Conclusion: In this real-life study, the median PFS was 31 months for the total cohort, even longer than in the referent CLEOPATRA trial, which confirms the effectiveness of dual antiHER2 therapy in a real-world setting. No possible clinical or pathological predictors of long-term response were identified, but larger studies may be able to distinguish patients’ characteristics associated with long-term response. Table 1: A comparison of clinical and pathological characteristics between the group of long-term responders and short-term responders Citation Format: Marija Križić, Tajana Silovski, Marina Popović, Natalija Dedić Plavetić. Real-world efficaccy of dual antiHER2 therapy in first line metastatic HER2-positive breast cancer and the possibility of prediction of long-term response [abstract]. In: Proceedings of the 2022 San Antonio Breast Cancer Symposium; 2022 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2023;83(5 Suppl):Abstract nr P4-01-39.
APA, Harvard, Vancouver, ISO, and other styles
2

Kubát, J., J. Klír, and D. Pova. "The dry nitrogen yields nitrogen uptake, and the efficacy on nitrogen fertilisation in long-term experiment in Prague." Plant, Soil and Environment 49, No. 8 (December 10, 2011): 337–45. http://dx.doi.org/10.17221/4134-pse.

Full text
Abstract:
Long-term field experiments conducted under different soil and climate conditions and their databases provide invaluable information and are indispensable means in the study of the productivity and sustainability of the soil management systems. We evaluated the results of the dry matter yields of the main products obtained with four variants of organic and mineral fertilisation in three long-term field experiments established in 1955. The experiments differed in the cultivated crops. The period of evaluation was 12 and 16 years (1985–2000), respectively. The productivity of nine-year crop rotation was lower with the fertilised variants than that with the alternative growing of spring wheat and sugar beets. The dry matter yields on the Nil variants, however, were higher in the crop rotation than in the alternate sugar beet and spring wheat growing, apparently due to the symbiotic nitrogen fixation. The dry matter yields of sugar beet and mainly of spring wheat declined in almost all variants of fertilisation in the alternate sugar beet and spring wheat growing, over the evaluated time period. In spite of the relatively high dry matter production, the declining yields indicated a lower sustainability of the alternate cropping system. Both organic and mineral fertilisation increased the production of the cultivated crops. The differences in the average dry matter yields were statistically significant. Both organic and mineral fertilisation enhanced significantly the N-uptake by the cultivated crops. The effectivity of nitrogen input was the highest with the alternate cropping of sugar beet and spring wheat indicating that it was more demanding for the external N-input and thus less sustainable than nine-year crop rotation.
APA, Harvard, Vancouver, ISO, and other styles
3

Gilchrist, Richard H., and L. Eugene Arnold. "Long-Term Efficacy of ADHD." Psychiatric Annals 38, no. 1 (January 1, 2008): 52–57. http://dx.doi.org/10.3928/00485713-20080101-03.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Gilchrist, Richard H., and L. Eugene Arnold. "Long-Term Efficacy of ADHD." Pediatric Annals 37, no. 1 (January 1, 2008): 46–51. http://dx.doi.org/10.3928/00904481-20080101-05.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Tanyeri, Hasan, Senol Polat, Ceyda Kirisolu, and Gediz Serin. "Long-Term Efficacy of Uvulopalatopharyngoplasty." Otolaryngology–Head and Neck Surgery 143, no. 2_suppl (August 2010): P50. http://dx.doi.org/10.1016/j.otohns.2010.06.040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

JANCIN, BRUCE. "Denosumab Delivered Long-Term Efficacy." Family Practice News 41, no. 17 (October 2011): 16–17. http://dx.doi.org/10.1016/s0300-7073(11)70895-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Lader, M. "Long-term efficacy in GAD." European Neuropsychopharmacology 11 (January 2001): S160—S161. http://dx.doi.org/10.1016/s0924-977x(01)80092-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Tolleth, H. "Long-term efficacy of collagen." Aesthetic Plastic Surgery 9, no. 2 (June 1985): 155–58. http://dx.doi.org/10.1007/bf01570349.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Kane, John. "Progress defined-short-term efficacy, long-term effectiveness." International Clinical Psychopharmacology 16, Supplement 1 (January 2001): S1—S8. http://dx.doi.org/10.1097/00004850-200101001-00002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Q, Cai. "Long Term Paired Outcomes of Index and Redo per Oral Endoscopic Myotomy." Gastroenterology & Hepatology International Journal 9, no. 1 (February 28, 2024): 1–8. http://dx.doi.org/10.23880/ghij-16000214.

Full text
Abstract:
Introduction: Per-Oral Endoscopic Myotomy (POEM) is a specialized procedure designed to improve symptoms by minimizing lower esophageal sphincter pressure in patients with achalasia. Despite excellent reported success rates, about 10% of patients have persistent or recurrent symptoms after procedure. There are limited studies looking at the efficacy of redo POEMS for these patients. In particular, there is no published data on comparing the paired effect of index POEM and redo POEM individually. We aimed to compare paired data of index and redo POEMs and provide election criteria for redo POEM. Methods: We conducted a retrospective observational study of all patients who underwent both index and redo POEM between August 2014 and January 2020 at Emory University. All patients underwent standard POEM protocol. We defined clinical success by an Eckardt score <3 post procedure. Results were analyzed with t tests, Chi squared tests where appropriate, or were otherwise reported as means with corresponding ranges. Results: 15 patients underwent redo POEM (ages 25-79, 53% female). One was lost to long-term follow up. There was no significant difference noted between index and redo POEM in procedure time (61.9 minutes vs. 62.2 minutes) (p=0.96), myotomy length (6.9 cm vs.6.1 cm) (p=0.13). 10 out of 15 patients (67%) achieved clinical success post-procedure with an Eckhardt score <3. Conclusion: Redo POEM procedure can be safely performed even on the same side of index POEM. Patients with previous interventions, those who clinically failed index POEM (never-responders), and those who initial responded (recurred) all can benefit from and should be offered redo POEM procedure. However, patients with severely diffusely dilated esophagus may not benefit from redo POEM and warrant surgical consultation for esophagectomy, if necessary.
APA, Harvard, Vancouver, ISO, and other styles
11

Bankhead, C. "Rabeprazole: long-term efficacy in GERD." Inpharma Weekly &NA;, no. 1371/1372 (January 2003): 11–12. http://dx.doi.org/10.2165/00128413-200313710-00025.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Ochmann, Uta, Rudolf A. Jörres, and Dennis Nowak. "Long-term Efficacy of Pulmonary Rehabilitation." Journal of Cardiopulmonary Rehabilitation and Prevention 32, no. 3 (2012): 117–26. http://dx.doi.org/10.1097/hcr.0b013e3182467194.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Hafner, Tomaz, Lawrence DuBuske, and Mitja Kosnik. "Long-term efficacy of venom immunotherapy." Annals of Allergy, Asthma & Immunology 100, no. 2 (February 2008): 162–65. http://dx.doi.org/10.1016/s1081-1206(10)60425-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

WORCESTER, SHARON. "Adalimumab Shows Long-Term Safety, Efficacy." Skin & Allergy News 39, no. 3 (March 2008): 44. http://dx.doi.org/10.1016/s0037-6337(08)70164-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

TURNER, ROBIN. "CO2 Laser Offers Long-Term Efficacy." Skin & Allergy News 39, no. 9 (September 2008): 31. http://dx.doi.org/10.1016/s0037-6337(08)70668-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Lecrubier, Y. "Long-term treatment of depression." European Psychiatry 8, S1 (1993): 13s—16s. http://dx.doi.org/10.1017/s0924933800004144.

Full text
Abstract:
SummaryLong-term treatment with antidepressants is now an accepted strategy in the management of depression. The demonstration of efficacy in this setting requires specific placebo-controlled trials of patients with recurrent depression studied after an adequate period of euthymia and for a long period of follow-up. This review examines the evidence for the prophylactic efficacy of antidepressant therapy with particular emphasis on the selective serotonin reuptake inhibitor, paroxetine.
APA, Harvard, Vancouver, ISO, and other styles
17

&NA;. "SPf66 malaria vaccine: partial long-term efficacy." Inpharma Weekly &NA;, no. 1050 (August 1996): 11. http://dx.doi.org/10.2165/00128413-199610500-00021.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Goadsby, Peter J., Uwe Reuter, Michel Lanteri-Minet, Gabriel Paiva da Silva Lima, Peggy Hours-Zesiger, Chrystel Fernandes, Shihua Wen, et al. "Long-term Efficacy and Safety of Erenumab." Neurology 96, no. 22 (April 28, 2021): e2724-e2735. http://dx.doi.org/10.1212/wnl.0000000000012029.

Full text
Abstract:
ObjectiveTo report the efficacy and safety of erenumab among patients with episodic migraine (EM) who were unsuccessful on 2 to 4 preventive treatments observed at week 64 of the open-label extension phase (OLEP) of A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies (LIBERTY) study (ClinicalTrials.govNCT03096834).MethodsThe OLEP, evaluating monthly erenumab 140 mg for 3 years, enrolled 240 patients who completed the double-blind treatment phase (DBTP) of 12 weeks during which they received placebo or erenumab 140 mg subcutaneous injections every 4 weeks as monotherapy. Efficacy outcomes were evaluated through the initial 52 weeks of OLEP (from DBTP baseline to total 64 weeks) in the overall population, patients receiving erenumab in DBTP, and patients from the DBTP placebo arm who switched to erenumab in OLEP. Endpoints included reduction of ≥50% in monthly migraine days (MMD) from DBTP baseline and change in MMD from DBTP baseline, Headache Impact Test score, and Migraine Physical Function Impact Diary score (Physical Impairment and Everyday Activities).ResultsAltogether, the week 52 visit of the OLEP was completed by 204 of 240 (85.0%) patients. Among patients continuing erenumab, the 50% responder rate increased from 29.9% at weeks 9 to 12 to 44.3% at weeks 61 to 64. The 50% responder rate in patients who initiated erenumab in the OLEP remained higher in the OLEP (50.0% at week 61–64) than during DBTP (14.2% at weeks 9–12) compared to patients in continuous erenumab arm. In the OLEP, the 50% responder rate for the overall population increased from weeks 13 to 16 until weeks 37 to 40 and then remained stable through weeks 61 to 64. Patients treated with erenumab in DBTP showed sustained effects on all efficacy outcomes; those initiating erenumab in the OLEP demonstrated continued improvement from week 13 onward. Adverse events (AEs) were reported, considering both treatment groups, by ≈80.8% (serious AEs by 6.7%), 76.3% (5.9%) in the continuing erenumab arm, and 85.2% (7.4%) in those starting erenumab in OLEP. No deaths were reported.ConclusionsIn patients with EM who were unsuccessful on 2 to 4 prior preventive treatments, the LIBERTY study demonstrated sustained efficacy on erenumab monotherapy treatment through 64 weeks in both treatment arms. Safety of erenumab was consistent with that observed in previous clinical trials.Trial Registration InformationClinicalTrials.govIdentifier: NCT03096834.Classification of EvidenceThe current study provides Class IV evidence on data from patients with EM that erenumab is safe and provides sustained efficacy at 52 weeks.
APA, Harvard, Vancouver, ISO, and other styles
19

Bae, Woo-Yong, Tae-Hoon Lee, Hyun-Jik Lee, Soo-Yong Ahn, Tae-Woo Gu, Jae-Ryong Kim, and Dong-Young Kim. "Long Term Efficacy of Coblator® Turbinoplasty." Journal of Clinical Otolaryngology Head and Neck Surgery 17, no. 1 (May 2006): 79–82. http://dx.doi.org/10.35420/jcohns.2006.17.1.79.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Sweta, V. S. Ananya, Jananni Muthu, B. Pratebha, and R. Saravana Kumar. "Long term efficacy of root coverage techniques." IP International Journal of Periodontology and Implantology 6, no. 2 (July 15, 2021): 79–87. http://dx.doi.org/10.18231/j.ijpi.2021.014.

Full text
Abstract:
Gingival recession is a dramatic soft tissue finding in teeth affected by periodontal disease and remains one of the most common aesthetic concerns associated with periodontal tissue. The etiology of the condition is multifactorial but is commonly associated with alveolar morphology, tooth brushing, mechanical trauma and periodontal disease. With greater understanding of the dynamics of healing along with an awareness of aesthetics various periodontal procedures have been introduced to deal with problems of gingival recession. The long-term stability of the outcomes obtained with the surgical treatment of single and multiple gingival recessions has been evaluated in a few studies. Of the vast repertoire of mucogingival procedures for gingival recession management, long term studies of more than 5 years is present only for coronally advanced flap with or without connective tissue grafts. There are many other novel techniques in literature with little or no evidence to prove its long term efficacy. Various studies published during the last 30 years were identified through a search of the PubMed/Medline, Science Direct and Cochrane Library databases. “Follow up”, “root coverage”, root coverage procedures, root coverage techniques were the key words used for the search. In this review we have grouped the efficacy of various root coverage techniques based on their short and long term follow up. The review emphasises the value of meticulous follow up in order to validate efficacy of root coverage techniques. It also discusses the factors responsible for stability of results.
APA, Harvard, Vancouver, ISO, and other styles
21

Gerdes, S., and J. Albrecht. "Long‐term efficacy: the new gold standard?" British Journal of Dermatology 185, no. 6 (October 10, 2021): 1086–87. http://dx.doi.org/10.1111/bjd.20715.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

&NA;. "Pranlukast demonstrates long-term efficacy in asthma." Inpharma Weekly &NA;, no. 1303 (September 2001): 6. http://dx.doi.org/10.2165/00128413-200113030-00015.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Morrison, Vicki A., Gary R. Johnson, Kenneth E. Schmader, Myron J. Levin, Jane H. Zhang, David J. Looney, Robert Betts, et al. "Long-term Persistence of Zoster Vaccine Efficacy." Clinical Infectious Diseases 60, no. 6 (November 20, 2014): 900–909. http://dx.doi.org/10.1093/cid/ciu918.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

McHugh, Jessica. "Long-term efficacy of canakinumab in crFMF." Nature Reviews Rheumatology 16, no. 8 (July 2, 2020): 408. http://dx.doi.org/10.1038/s41584-020-0466-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
25

Ruck, Tobias, Stefan Bittner, Tanja Kuhlmann, Heinz Wiendl, and Sven G. Meuth. "Long-term efficacy of alemtuzumab in polymyositis." Rheumatology 54, no. 3 (December 30, 2014): 560–62. http://dx.doi.org/10.1093/rheumatology/keu484.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

Kane, John M., John Lauriello, Eugene Laska, Michael Di Marino, and Curt D. Wolfgang. "Long-Term Efficacy and Safety of Iloperidone." Journal of Clinical Psychopharmacology 28, Suppl. 1 (April 2008): S29—S35. http://dx.doi.org/10.1097/jcp.0b013e318169cca7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
27

Shingleton, Bradford J., Claudia U. Richter, Shashi K. Dharma, Lucene Tong, A. Robert Bellows, B. Thomas Hutchinson, and Robert J. Glynn. "Long-term Efficacy of Argon Laser Trabeculoplasty." Ophthalmology 100, no. 9 (September 1993): 1324–29. http://dx.doi.org/10.1016/s0161-6420(93)31480-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
28

ZOLER, MITCHEL L. "Abatacept Shows Long-Term Efficacy for JIA." Internal Medicine News 42, no. 18 (October 2009): 36. http://dx.doi.org/10.1016/s1097-8690(09)70734-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
29

Rosa, J., J. Kvasnicka, L. Lambert, P. Waldauf, T. Zelinka, O. Petrak, B. Strauch, et al. "PREDICTION OF LONG-TERM RENAL DENERVATION EFFICACY." Journal of Hypertension 36, Supplement 1 (June 2018): e48. http://dx.doi.org/10.1097/01.hjh.0000539091.97172.94.

Full text
APA, Harvard, Vancouver, ISO, and other styles
30

O'Connor, Paul, Giancarlo Comi, Mark S. Freedman, Aaron E. Miller, Ludwig Kappos, Jean-Pierre Bouchard, Christine Lebrun-Frenay, et al. "Long-term safety and efficacy of teriflunomide." Neurology 86, no. 10 (February 10, 2016): 920–30. http://dx.doi.org/10.1212/wnl.0000000000002441.

Full text
APA, Harvard, Vancouver, ISO, and other styles
31

Ault, Kevin A. "Long-term efficacy of human papillomavirus vaccination." Gynecologic Oncology 107, no. 2 (November 2007): S27—S30. http://dx.doi.org/10.1016/j.ygyno.2007.07.078.

Full text
APA, Harvard, Vancouver, ISO, and other styles
32

Rak, I., and J. Raniwalla. "Maintenance of long-term efficacy with ‘seroquel’." Schizophrenia Research 41, no. 1 (January 2000): 205. http://dx.doi.org/10.1016/s0920-9964(00)90806-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Meltzer, H. Y. "Long-term efficacy of ziprasidone in schizophrenia." European Neuropsychopharmacology 11 (January 2001): S273. http://dx.doi.org/10.1016/s0924-977x(01)80340-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
34

Shingleton, Bradford J., Claudia U. Richter, A. Robert Bellows, B. Thomas Hutchinson, and Robert J. Glynn. "Long-term Efficacy of Argon Laser Trabeculoplasty." Ophthalmology 94, no. 12 (December 1987): 1513–18. http://dx.doi.org/10.1016/s0161-6420(87)33253-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
35

Madariaga, J. R., J. Reyes, G. Mazariegos, J. J. Fung, T. E. Starzl, and K. Abu-Elmagd. "The long-term efficacy of multivisceral transplantation." Transplantation Proceedings 32, no. 6 (September 2000): 1219–20. http://dx.doi.org/10.1016/s0041-1345(00)01195-7.

Full text
APA, Harvard, Vancouver, ISO, and other styles
36

Cavaliere, Carlo, Elona Begvarfaj, Cristoforo Incorvaia, Bruno Sposato, Marco Brunori, Andrea Ciofalo, Antonio Greco, Marco de Vincentiis, and Simonetta Masieri. "Long-term omalizumab efficacy in allergic rhinitis." Immunology Letters 227 (November 2020): 81–87. http://dx.doi.org/10.1016/j.imlet.2020.08.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Valle, RF. "Hysteroscopic sterilization: long-term safety and efficacy." Contraception 72, no. 3 (September 2005): 237. http://dx.doi.org/10.1016/j.contraception.2005.06.028.

Full text
APA, Harvard, Vancouver, ISO, and other styles
38

Dinneen, S. F., C. C. Cronin, and D. J. O’Sullivan. "Long term efficacy of a pen injector." Irish Journal of Medical Science 160, no. 9 (January 1991): 286–87. http://dx.doi.org/10.1007/bf02948414.

Full text
APA, Harvard, Vancouver, ISO, and other styles
39

Castelo-Soccio, Leslie, and Abby S. Van Voorhees. "Long-term efficacy of biologics in dermatology." Dermatologic Therapy 22, no. 1 (January 2009): 22–33. http://dx.doi.org/10.1111/j.1529-8019.2008.01213.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
40

Brandt, Carlos T., Leo J. Rothbarth, David Kumpe, Frederick M. Karrer, and John R. Lilly. "Splenic embolization in children: Long-term efficacy." Journal of Pediatric Surgery 24, no. 7 (July 1989): 642–45. http://dx.doi.org/10.1016/s0022-3468(89)80710-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
41

Cappellini, Maria Domenica. "Long-term efficacy and safety of deferasirox." Blood Reviews 22 (December 2008): S35—S41. http://dx.doi.org/10.1016/s0268-960x(08)70007-9.

Full text
APA, Harvard, Vancouver, ISO, and other styles
42

Gallitto, Enrico, Gianluca Faggioli, Chiara Mascoli, Rodolfo Pini, Paolo Spath, Teresa Gabellini, Andrea Stella, and Mauro Gargiulo. "Long-term EVAR Efficacy in Young Patients." European Journal of Vascular and Endovascular Surgery 58, no. 6 (December 2019): e297. http://dx.doi.org/10.1016/j.ejvs.2019.06.904.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Elsas, T., and H. Johnsen. "Long-term efficacy of primary laser trabeculoplasty." British Journal of Ophthalmology 75, no. 1 (January 1, 1991): 34–37. http://dx.doi.org/10.1136/bjo.75.1.34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
44

Kvasnička, Jan, Lukáš Lambert, Petr Waldauf, Tomáš Zelinka, Ondřej Petrák, Branislav Štrauch, Robert Holaj, et al. "(Prediction of long-term renal denervation efficacy)." Cor et Vasa 61, no. 4 (August 11, 2019): e378-e384. http://dx.doi.org/10.1016/j.crvasa.2018.09.007.

Full text
APA, Harvard, Vancouver, ISO, and other styles
45

Eriksson, Mats, Dragos Budinski, and Neil Hounslow. "Long-term efficacy of pitavastatin versus simvastatin." Advances in Therapy 28, no. 9 (August 25, 2011): 799–810. http://dx.doi.org/10.1007/s12325-011-0057-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
46

Doebbeling, Bradley N. "Long-term Efficacy of Intranasal Mupirocin Ointment." Archives of Internal Medicine 154, no. 13 (July 11, 1994): 1505. http://dx.doi.org/10.1001/archinte.1994.00420130101013.

Full text
APA, Harvard, Vancouver, ISO, and other styles
47

Cohen, Jerome. "Long-Term Efficacy and Safety of Terazosin." Journal of Clinical Pharmacology 33, no. 3 (March 1993): 272–78. http://dx.doi.org/10.1002/j.1552-4604.1993.tb03956.x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
48

Moncrieff, Joanna. "Long-term effects of antipsychotics." BJPsych Advances 21, no. 2 (March 2015): 78–79. http://dx.doi.org/10.1192/apt.bp.114.012591.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Kingman, Albert. "Methods of Projecting Long-Term Relative Efficacy of Products Exhibiting Small Short-Term Efficacy." Caries Research 27, no. 4 (1993): 322–27. http://dx.doi.org/10.1159/000261561.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Kissling, W., S. Heres, K. Lloyd, E. Sacchetti, P. Bouhours, R. Medori, and P. M. Llorca. "Direct transition to long-acting risperidone - analysis of long-term efficacy." Journal of Psychopharmacology 19, no. 5_suppl (September 2005): 15–21. http://dx.doi.org/10.1177/0269881105056514.

Full text
Abstract:
This report presents data from the extension phase of a 6-month trial that evaluated the efficacy of risperidone long-acting injectable (RLAI) in stable psychotic patients requiring a treatment change. Patients continued to receive RLAI every 2 weeks for a maximum of 12 months from study entry. Symptoms were assessed using the PANSS after 1, 3, 6, 9 and 12 months of treatment (or treatment endpoint). Remission of severity criteria were defined as ≤3 points in all PANSS items suggested by the Remission in Schizophrenia Working Group. 715 patients (63% male) entered the extension phase and 508 completed the 12-month study. The mean PANSS total score at Day 0 was 74.9±22.7. This was significantly reduced after 1 month (67.7 ±22.3, p≤0.001), with continued improvements over the 12 months of the study until treatment endpoint (59.7±21.9). Significant improvements from Day 0 to endpoint were also seen in the scores for all PANSS subscales and symptom factors. The proportion of patients who met the PANSS severity criteria for remission increased from 29% at Day 0 to 60% at endpoint, and the proportion of patients who met these criteria for ≤ 6 months increased from 24% at Month 6 to 45% at endpoint. Treatment with RLAI for up to 12 months provided significant and sustained improvements in symptom control in patients with schizophrenia. These improvements may help patients to achieve and remain in remission.
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Long-Term efficaccy' for other source types:
Dissertations / Theses Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography